Forte Biosciences, Inc.
Forte Biosciences develops FB102, a monoclonal antibody in clinical trials targeting CD122 to treat autoimmune diseases including celiac disease, vitiligo, and alopecia areata. The company has completed Phase 1 testing in healthy volunteers and reported positive Phase 1b results in celiac disease, with Phase 2 trials underway.
Forte Biosciences, Inc is a Healthcare company operating in Biotechnology with a $377.2M market cap.
FBRX missed consensus EPS by 0.1% in Q1 FY2026, reported Mar 31, 2026.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks FBRX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for FBRX.
$ curl https://api.spokenalpha.com/v1/companies/FBRXFAQ
Spoken Alpha indexes FBRX's earnings call transcripts at https://spokenalpha.com/companies/FBRX. Each call links to attributed speakers and parsed analyst Q&A. Forte Biosciences, Inc.'s own investor relations page is at https://www.fortebiorx.com/investor-relations/news/default.aspx.
Forte Biosciences, Inc. (FBRX) held its most recent earnings call on 2021-05-11, covering fiscal Q1 2021.
Forte Biosciences, Inc. (FBRX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-03-31 | $-1.24 | $-1.16 | -6.9% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-1.45 | $-1.15 | -26.4% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-0.99 | $-0.08 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.96 | $-1.11 | +13.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-1.37 | $-0.95 | -44.2% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-27 | $-1.17 | $-0.14 | -100.0% | $38.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-4.54 | $-7.12 | +36.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.27 | $-0.17 | -58.8% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.16 | $-0.16 | 0.0% | $6.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-17 | $-0.19 | $-0.28 | +32.1% | $6.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.26 | $-0.57 | +54.4% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.42 | $-0.42 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.23 | $-0.32 | +27.4% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.23 | $-0.16 | -43.8% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.18 | $-0.15 | -20.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.21 | $-0.32 | +34.4% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.17 | $-0.17 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.21 | $-0.32 | +34.4% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-07 | $-0.54 | $-0.36 | -50.0% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.43 | $-0.43 | 0.0% | $0 | — | — | EODHD |
Source: EODHD. FBRX reported actuals as published; sparse fields render as —.
Repeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2021 | $2.96 | $3.06 | -3.4% | +0.2% | -2.1% |
| Q4 FY2021 | $2.73 | $3.14 | -13.0% | -2.9% | -2.1% |
| Q3 FY2021 | $2.70 | $3.22 | -16.2% | -0.8% | -0.3% |
| Q2 FY2021 | $2.82 | $3.18 | -11.4% | +2.3% | +1.9% |
| Q1 FY2020 | $2.74 | $3.09 | -11.2% | +3.0% | +2.1% |
OTHER since 2024 • 1/2 beats (50%) • last guidance cut Q2 FY2021
| Q4 FY2020 |
| $2.88 |
| $3.11 |
| -7.3% |
| +1.6% |
| +1.7% |
| Q3 FY2020 | $3.02 | $3.12 | -3.2% | +2.8% | +1.4% |
| Q2 FY2020 | $3.21 | $3.31 | -3.0% | -6.6% | -7.6% |
| Q1 FY2019 | $2.86 | $3.33 | -14.0% | -3.7% | -0.9% |
| Q4 FY2019 | $2.83 | $3.21 | -11.8% | -3.4% | -1.4% |